Objective and design The pro-oxidative and pro-inflammatory pathways in vascular endothelium have been implicated in the development of atherosclerosis. In the present study, we investigated effect of interleukin-4 (IL-4) on monocyte chemoattractant protein-1 (MCP-1) expression in vascular endothelium and examined the role of distinct sources of reactive oxygen species (ROS) in this process. 
Introduction
Monocyte chemoattractant protein-1 (MCP-1) is the best characterized member of the CC chemokine family and plays a key role in recruitment of monocytes into the arterial wall and transmigration into the subendothelial regions of the vessels. MCP-1 is expressed and released by various types of cells within the vessel wall, including endothelial cells and smooth muscle cells, in response to a number of extracellular stimuli such as cytokines and platelet-derived growth factor (PDGF) [1] [2] [3] [4] [5] [6] . Compelling evidence has demonstrated the pivotal role of MCP-1 in the pathogenesis of atherosclerosis. For example, both MCP-1 mRNA and protein expression have been detected in early atherosclerotic lesions by immunostaining, northern blot analysis, and in situ hybridization [7] [8] [9] . Additionally, MCP-1 deficiency significantly reduced atherosclerosis in low density lipoprotein (LDL) receptor-deficient mice and human apolipoprotein B (ApoB)-expressing transgenic mice [10, 11] . It was also found that the deletion of CCR2, the corresponding receptor for MCP-1, markedly decreased atherosclerotic lesion formation in ApoE-deficient mice [12] . On the other hand, Aiello et al. [13] reported that enhanced expression of MCP-1 by transplantation of MCP-1 overexpressing bone marrow cells accelerated atherosclerosis in ApoE-deficient mice. Furthermore, human clinical studies have shown that patients with coronary artery disease had significantly elevated MCP-1 serum levels [14] . Finally, anti-MCP-1 gene therapy successfully attenuated atherosclerosis in ApoE-deficient mice [15, 16] , suggesting MCP-1 as a potential therapeutic target in atherosclerosis. These studies clearly demonstrate that MCP-1 plays a fundamental role in the pro-inflammatory pathways in vascular endothelium and serves as a contributing factor to atherosclerosis.
Although the contribution of T-helper 1 (Th1) and T-helper 2 (Th2) cell responses to the development of atherosclerosis remains unclear, pro-inflammatory cytokines secreted by Th1 cells (Th1 cytokines) have been implicated in the initiation and progression of atherosclerosis. For example, interferon-c (INF-c) is a well-known pro-atherogenic cytokine, and pathophysiological role of INF-c in atherosclerosis has been extensively investigated both in vitro and in vivo [17] . Recent evidence, however, has shown that the development of atherosclerosis was not completely abolished even though disruption of INF-c gene significantly diminished the severity of this disease in LDLR-deficient mice [18] . These findings suggest that other pathways may contribute to the disease progression. Indeed, there is evidence that Th2 cells might play a role while little is known concerning the possible contribution of Th2 cytokines to vascular inflammation and atherosclerosis [1, 2, [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] .
Interleukin-4 (IL-4) is a pleiotropic immunomodulatory cytokine secreted by Th2 cells (Th2 cytokines) and was traditionally considered as an anti-inflammatory cytokine [31, 33] . However, a growing body of evidence has suggested that IL-4 is pro-atherogenic and may play a critical role in the progression of atherosclerosis. For example, recent studies from our laboratory and others have demonstrated that IL-4 induces pro-inflammatory environments by overexpressing a number of pro-inflammatory mediators, such as vascular cell adhesion molecule-1 (VCAM-1), E-selectin, MCP-1, and interleukin-6 (IL-6) in human vascular endothelial cells [1, 2, 22-24, 26-29, 34, 35] . It was also found that IL-4 synergistically increases IL-1b-, TNF-a-, or lipopolysaccharide (LPS)-induced VCAM-1 expression in vascular endothelium [19, 20, 30] . In addition to in vitro cell culture studies, pro-atherogenic effects of IL-4 have been investigated in animal models of atherosclerosis. King et al. [25] have shown that transplantation of bone marrow stem cells isolated from IL-4-deficient (IL-4 -/-) mice led to decreased atherosclerotic lesion formation in LDL receptor-deficient (LDLR -/-) mice.
Furthermore, a significant reduction in atherosclerotic plaque area was observed in IL-4 -/-/ApoE -/-mice compared to ApoE -/-mice [21] . These findings suggest that there may be potential, novel pathways by which IL-4 exerts its pro-atherogenic effects. The molecular signaling mechanisms responsible for IL-4-induced pro-inflammatory pathways in vascular endothelium, however, remain largely unknown.
In the present study, we investigated the effect of IL-4 on MCP-1 expression in vitro and in vivo. We also examined the potential role of distinct sources of reactive oxygen species (ROS) in this process. We demonstrated that IL-4 significantly up-regulates mRNA and protein expression of MCP-1 in vascular endothelium through NADPH oxidase (NOX)-mediated ROS generation.
Materials and methods

Cell culture
Primary human aortic endothelial cells (HAEC) were purchased from Cascade Biologics TM (Portland, OR) and cultured in medium 200 supplemented with low serum growth supplement (LSGS) in a 37°C, 5% CO 2 /95% air, humidified cell culture incubator.
Interleukin-4
Recombinant human and mouse IL-4 were purchased from R&D Systems Inc. (Minneapolis, MN) and dissolved in sterile phosphate buffered saline (PBS). Based on previous literature data from our group and others [1, 2, 19, 20, 22-24, 26-30, 34-40] , concentrations of 0.1-10 ng/ml and 100 lg/kg of IL-4 were employed for in vitro and in vivo studies, respectively.
Animals
Male C57BL/6 mice (6 weeks old) were purchased from Harlan (Indianapolis, IN) and maintained under environmentally controlled conditions, and subject to a 12 h light/ dark cycle with food and water ad libitum. Additionally, NOX knockout mice (NOX gp91 phox-/-or B6.129S6-Cybb tm1Din /J, male, 6 weeks old) and matched wild-type controls with the same genetic background (C57BL/6J, male, 6 weeks old) were obtained from The Jackson Laboratory (Bar Harbor, ME). Animals (n = 4-5) received a single intraperitoneal injection of either PBS or 100 lg/kg of IL-4, and were humanely killed by CO 2 inhalation. The aortas from mice in each group were collected and dissected gently free of adhering tissues. Isolated aortic samples were frozen and stored at -80°C until analysis. In addition, blood was obtained by cardiac puncture, and blood plasmas were prepared, aliquoted, frozen, and stored at -80°C. Freshly thawed blood plasmas were analyzed immediately. The investigation conforms to the Guide for the Care and Use of Laboratory Animals published by the United States National Institutes of Health (NIH Publication No. 85-23, revised 1996) and this study was approved by the Virginia Tech Institutional Animal Care and Use Committee (IACUC).
Real-time reverse transcriptase-polymerase chain reaction (RT-PCR)
The aortas of mice were homogenized with 1.6 mm stainless steel beads and 1 ml of TRI Reagent (SigmaAldrich, St. Louis, MO) using a setting of 8 for 15 min in a tissue homogenizer (The Bullet Blender TM , Next Advance Inc., Averill Park, NY), and total RNA was isolated from tissue homogenates as described previously [35, 41] . In cell culture studies, total RNA was isolated from HAEC using the RNeasy Mini Kit (Qiagen, Valencia, CA) according to the protocol of the manufacturer. One lg of total RNA was reverse-transcribed at 25°C for 15 min, 42°C for 45 min, and 99°C for 5 min in 20 ll of 5 mM MgCl 2 , 10 mM Tris-HCl, pH 9.0, 50 mM KCl, 0.1% Triton X-100, 1 mM dNTP, 1 U/ll of recombinant RNasin ribonuclease inhibitor, 15 U/lg of AMV reverse transcriptase, and 0.5 lg of random hexamers. Amplifications of individual genes were performed on ABI 7300 Sequence Detection System (Applied Biosystems, Foster City, CA) using TaqMan Ò Universal PCR Master Mix, gene-specific TaqMan PCR probes and primers, and a standard thermal cycler protocol (50°C for 2 min before the first cycle, 95°C for 15 s, and 60°C for 1 min, repeated 45 times). For specific probes and primers of PCR amplifications, TaqMan Ò Gene Expression Assay Reagents for human MCP-1, human glyceraldehyde-3-phosphate dehydrogenase (GAPDH), mouse MCP-1, and mouse GAPDH were obtained from Applied Biosystems. The threshold cycle (C T ), which indicates the fractional cycle number at which the amount of amplified target gene reaches a fixed threshold, from each well was determined by the Applied Biosystems Sequence Detection Software v1.2.3. Relative quantification, which represents the change in gene expression from real-time quantitative PCR experiments between the treated group and untreated control group, was calculated by the comparative C T method as described previously [35, [42] [43] [44] . The data were analyzed using the equation 2 -DDCT , where [43] . It provides a quick and efficient system for quantitative determination of monocyte/macrophage migration. The migratory cells on the bottom of the insert membrane were dissociated from the membrane when incubated with cell detachment buffer. These cells were subsequently lysed and detected by the CyQuant GR dye. This green fluorescent dye exhibits strong fluorescence enhancement when bound to cellular nucleic acids. The fluorescence was measured by a fluorescence multi-well plate reader with excitation and emission wavelengths of 480 and 520 nm.
Detection of ROS
The intracellular levels of ROS were measured by DCF fluorescence staining using a Zeiss AXIO Imager A1m fluorescence microscope equipped with AxioCam MRc5 Digital Imaging System (Carl Zeiss MicroImaging, Inc., Thornwood, NY). Briefly, HAEC were grown on the glass slide in the Lab-Tek Ò II Chamber Slide TM System (Nalge Nunc International Corp., Naperville, IL). After treatment with IL-4, the cells were loaded with carboxy-H 2 DCF-DA (Invitrogen Corp., Carlsbad, CA) at a concentration of 5 lM in PBS for 30 min at 37°C in 5% CO 2 /95% air, humidified cell culture incubator. HAEC monolayers were washed with PBS and examined on a Zeiss AXIO Imager A1m fluorescence microscope. Cell images were acquired with 209 objective by AxioCam MRc5 Digital Imaging System.
Statistical analysis
Statistical analysis of data was completed using SigmaStat 3.5 (Systat Software, Inc., Point Richmond, CA). One-way ANOVA was used to compare mean responses among the treatments. For each endpoint, the treatment means was compared using the Bonferroni least significant difference procedure. Differences among the means were considered significant at p \ 0.05.
Results
IL-4 up-regulates MCP-1 expression in HAEC and mice
The recruitment of blood leukocytes and their migration throughout the vascular endothelium are thought to be critical early pathologic events in atherogenesis. These processes are directly facilitated by enhanced expression of pro-inflammatory chemokines and chemokine receptors in activated endothelial cells and leukocytes [45] [46] [47] [48] [49] . In the present study, we investigated the effect of IL-4 on MCP-1 expression in HAEC and monocyte migration. Quantitative real-time RT-PCR showed that treatment of HAEC with increasing concentrations of IL-4 (0.1, 1.0, and 10 ng/ml) significantly and dose-dependently up-regulated mRNA expression of MCP-1 (Fig. 1a) . Consistent with the data on gene expression, exposure of HAEC to IL-4 resulted in a significant and dose-dependent up-regulation of MCP-1 protein expression (Fig. 1b) . To verify the functional integrity of MCP-1 induced by IL-4-activated HAEC, monocyte migration assays were conducted. As shown in Fig. 2 , treatment of HAEC with IL-4 significantly increased the migration of THP-1 human monocytic leukemia cells. To examine the critical role of MCP-1 in IL-4-induced monocyte migration, conditioned media (CM) from IL-4-treated HAEC were pre-incubated with either non-immune isotype control IgG (negative control) or neutralizing anti-MCP-1 antibody. Enhanced migration of THP-1 cells was significantly attenuated by pre-incubation of the CM with neutralizing anti-MCP-1 antibody, while it was not affected by pre-incubation of the CM with nonimmune isotype control IgG (Fig. 2) . These data clearly demonstrated that IL-4-induced MCP-1 expression in HAEC is critically involved in stimulation of monocyte migration.
We also performed a series of animal experiments to examine whether IL-4 induces MCP-1 expression in vivo. As depicted in Fig. 3a , real-time RT-PCR analysis demonstrated a significant up-regulation of MCP-1 mRNA expression in mouse aortas collected 4 h after intraperitoneal administration of 100 lg/kg of IL-4. In addition, a significantly enhanced expression of MCP-1 protein was observed in both aortas and blood plasmas collected from mice 4 to 8 h after IL-4 injection (Fig. 3b, c) . These results provide the first direct evidence demonstrating that IL-4 induces MCP-1 expression in both HAEC and mice.
Antioxidants attenuate IL-4-induced MCP-1 expression in HAEC
It is generally accepted that ROS play a critical role in atherogenesis by regulating the expression of pro-inflammatory mediators such as cytokines, chemokines, and adhesion molecules in vascular endothelium [1, 3, 28, 34, 35, 50] . To determine whether IL-4-induced MCP-1 expression in HAEC is mediated through ROS generation, we examined the effect of antioxidants on mRNA and protein expression of MCP-1 in IL-4-treated HAEC. Pre-treatment of HAEC with the antioxidant pyrrolidine dithiocarbamate (PDTC) markedly attenuated IL-4-mediated up-regulation of MCP-1 mRNA and protein expression (Fig. 4a, b) . A similar effect was also observed in IL-4-activated HAEC pre-treated with epigallocatechin gallate (EGCG) (Fig. 4c, d ). Both PDTC and EGCG have been frequently used as antioxidant compounds to investigate redox regulation of the intracellular signaling pathways and of cell function [1, 28, 35, 51, 52] . In addition, we employed DCF fluorescence assay to examine if the antioxidants used in the present study decrease the IL-4-induced ROS generation in HAEC. As illustrated in Fig. 5 , IL-4-mediated increase in ROS production was 
Role of distinct sources of ROS in IL-4-induced MCP-1 expression
Previous studies have shown that NOX is a key source of enzymatic generation of ROS in a variety of cell types including endothelial cells [53] . To determine whether NOX is involved in IL-4-induced MCP-1 expression in vascular endothelium, HAEC were pre-treated with apocynin, an inhibitor of NOX, for 30 min and then further incubated with 10 ng/ml of IL-4. Figure 6 depicted that inhibition of NOX by apocynin significantly attenuated IL-4-induced MCP-1 mRNA and protein expression in HAEC (Fig. 6a, b) . We also employed diphenylene iodonium (DPI) to further elucidate the potential role of NOX in IL-4-induced MCP-1 expression in HAEC. As demonstrated in Fig. 6c, d , a significant reduction of IL-4-mediated upregulation of MCP-1 mRNA and protein expression was observed in HAEC pre-treated with increasing concentrations of DPI (10 and 20 lM). In addition, pre-treatment of HAEC with NOX inhibitors such as apocynin and DPI markedly suppressed IL-4-induced ROS generation as assessed by DCF fluorescence staining (Fig. 7) , indicating that IL-4 up-regulates MCP-1 expression in HAEC through NOX-mediated ROS generation. Furthermore, NOX knockout mice and matched wild-type controls were used to examine the crucial role of NOX in IL-4-induced MCP-1 expression in vivo. Consistent with the data on IL-4-induced up-regulation of MCP-1 expression in mice (Fig. 3) , IL-4 administration resulted in a significant increase in the mRNA expression of MCP-1 in wild-type (Fig. 8) . These results strongly suggest that NOX plays a pivotal role in IL-4-induced MCP-1 expression in vitro and in vivo.
Another enzymatic source of ROS generation is xanthine oxidase [53] . To investigate the potential contribution of xanthine oxidase-mediated ROS generation to MCP-1 expression in IL-4-activated vascular endothelium, HAEC were pre-treated with allopurinol, an inhibitor of xanthine oxidase, for 30 min and then incubated with 10 ng/ml of IL-4 for 16 h. Pre-treatment of HAEC with allopurinol at 1.0 and 10 lM did not affect IL-4-mediated up-regulation of MCP-1 expression (Fig. 9) , indicating that xanthine oxidase-mediated ROS generation is not associated with IL-4-induced MCP-1 expression in HAEC.
It is generally accepted that the mitochondrial electron transport chain is another major source of intracellular ROS production [53] . To determine the involvement of mitochondria in ROS-mediated MCP-1 overexpression in response to IL-4, HAEC were pre-treated with the mitochondrial electron transport chain inhibitors, such as rotenone, thenoyltrifluoroacetone (TTFA), or antimycin A, for 30 min to selectively block the electron flows between mitochondrial respiratory chain complexes, and then incubated with 10 ng/ml of IL-4 for 16 h. As shown in Fig. 10 , inhibitions of mitochondrial electron transport chain did not exert any significant effects on MCP-1 expression in IL-4-activated HAEC. These results suggest that mitochondrial electron transport chain-mediated ROS generation is not involved in IL-4-induced MCP-1 expression in HAEC.
Discussion
The present study demonstrated that IL-4 induces MCP-1 expression in human aortic endothelial cells and mouse aortas. However, we cannot exclude possible involvement of other cell types, such as smooth muscle cells and macrophages, in IL-4-induced MCP-1 expression in aortas. Therefore, we are currently conducting a series of immunofluorescence staining with dual-labeling procedures to further investigate the potential contribution of specific type of cells, such as endothelial cells, smooth muscle cells, and macrophages, to the induction of MCP-1 expression in mouse aortas after treatment with IL-4. Oxidative stress has been implicated in a number of inflammatory vascular diseases including atherosclerosis [3, 54] . For example, increased production of superoxide was observed in atherosclerotic human coronary arteries [55, 56] . It has become apparent that endothelial dysfunction is closely associated with an increased risk of atherosclerosis and vascular endothelial cells are particularly sensitive to oxidative stress [57, 58] . Heitzer et al. [59] demonstrated that elevated production of vascular ROS is linked to impaired endothelial function and progression of atherosclerosis in patients with coronary artery disease. In addition, oxidative stress up-regulates expression of pro-inflammatory mediators such as cytokines, chemokines, and adhesion molecules in vascular endothelium, which is one of the earliest steps in the development of atherosclerotic lesion formation [3, 60, 61] . Recent studies by our group and others highlight that IL-4 may be considered a pro-oxidative cytokine which increases the oxidizing potential of target cells [1, 28, 29, 35, 62] . For example, treatment with IL-4 resulted in a dose-dependent increase in intracellular ROS and subsequent overexpression of redox-responsive genes such as VCAM-1 and MCP-1 in human umbilical vein endothelial cells [1, 26, 28] . The distinct sources of ROS involved in the IL-4-induced MCP-1 expression, however, have not been reported. Therefore, we examined effects of various pharmacological inhibitors of ROS generating pathways, such as NOX, xanthine oxidase, and the mitochondrial electron transport chain, on IL-4-induced MCP-1 expression in HAEC. We used apocynin and allopurinol to selectively inhibit NOX and xanthine oxidase. Additionally, we employed rotenone as an inhibitor of complex I which blocks the electron flow from NADH dehydrogenase (complex I) to ubiquinone. TTFA was used as a complex II inhibitor which interferes with the electron transport from succinate dehydrogenase (complex II) to ubiquinone. We also used antimycin A to selectively inhibit the electron flow at complex III. Among these ROS generating pathways, the present study demonstrated that the inhibition of NOX by apocynin significantly attenuated IL-4-induced MCP-1 expression in HAEC while it was not affected by inhibiting other ROS generating pathways, such as xanthine oxidase and the mitochondrial electron transport chain. The potential role of NOX in IL-4-induced MCP-1 expression was also confirmed by pre-treatment of HAEC with DPI, a structurally unrelated NOX inhibitor. Even though pharmacological inhibitors of NOX have been widely used in a number of previous in vitro and in vivo studies [32, 53, 63] , it should be noted that they are not highly selective or specific. In addition to the pharmacological approach using NOX inhibitors such as apocynin and DPI, the genetic approach with NOX knockout mice further provided robust evidence in support of a central role for NOX in IL-4-induced MCP-1 expression in vascular endothelium. These findings suggest that at least one distinct ROS generating pathway mediates MCP-1 induction in human aortic endothelial cells and mouse aortas by IL-4.
In conclusion, we have demonstrated the first direct evidence indicating that IL-4 significantly up-regulates mRNA and protein expression of MCP-1 in vascular endothelium through NOX-dependent pathways. The present study will contribute to a better understanding of the molecular signaling mechanisms by which IL-4 mediates vascular inflammation and development of atherosclerosis. It will also provide insights to novel therapeutic approaches for atherosclerosis specifically targeted against pro-oxidative and pro-inflammatory pathways in vascular endothelium. 
